Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study

This article has no abstract
Epistemonikos ID: 1fc0e713791c02628c03f6a42d0f2fc2862056d0
First added on: Feb 15, 2025